Sinopharm Says Shot 79% effective; Looking for public use in China

A Peruvian health worker is preparing a syringe to inoculate a volunteer with the Sinopharm vaccine on December 9th.

Photographer: Ernesto Benavides / AFP / Getty Images

State-backed vaccine developer China National Biotec Group Co. stated that one of his photos is effective in preventing Covid-19 in 79.3% of people, allowing him to apply for marketing authorization for inoculation for use in the general population.

Provisional data show that the vaccine, which is already authorized for emergency use in China, is safe and the people who took the photos generated all high levels of antibodies, according to a statement published on the website of Beijing Biological Products Institute Co., a subsidiary of Sinopharm, CNBG parent.

The vaccine rate – one of two developed by CNBG – meets the minimum efficiency standard of 50% set by US regulators for emergency authorization of Covid vaccines. However, vaccines that use state – of – the – art RNA messenger technology Moderna Inc. and Pfizer Inc. produced much better results, reducing symptomatic cases of Covid by well over 90% in giant studies.

The rate announced on Wednesday for CNBG shooting is also lower than that reported in vaccine studies in the United Arab Emirates, which raised the level of protection to 86%.

CNBG, which filed an application with Chinese vaccine regulators last month, could become the first developer outside Russia to see its photos made available to the general public, underlining China’s determination to be a major player in providing vaccinations to countries around the world . Other countries have agreed to compete with Western vaccines only for emergency use.

China is fighting to make the world trust its vaccines

However, China faces a challenge in assuring governments and the millions of people who may have to rely on its vaccines for their safety and effectiveness. Chinese developers have been slow compared to their Western counterparts in communicating data, risking an erosion of confidence in these candidates, as the world focuses on the laser that vaccines are most successful in fighting the pandemic.

The lack of transparency was evident last week, according to studies for a vaccine by Chinese developer Sinovac Biotech Ltd. confusing results on how effective it is in protecting people against Covid-19.

A Brazilian official said the Sinovac shooting did not reach 90% effectiveness, while Turkey said a trial in its country showed a rate of 91%. Sinovac is still reconciling the results of independent phase III studies in Brazil, Turkey, Indonesia and Chile, a person familiar with the studies said last week.

Both Sinopharm and Sinovac are betting on successful vaccines to inoculate more people around the world and save lives. Chinese vaccines could also help their home country gain geopolitical influence and restore a tarnished image of criticism of its initial response to the virus.

The global promise

China has agreed to supply its vaccines to Covax, a World Health Organization-sponsored effort to provide vaccinations to developing nations. Chinese vaccines have the advantage of easier storage and distribution because they do not have to be frozen – unlike those from Pfizer and Moderna. They can be stored at normal refrigerator temperatures, facilitating distribution to rural areas and developing countries.

.Source